NEW YORK (AP) — Two scientists who paved the way for widely used vaccines and another who discovered key players in cell growth have been awarded prestigious medical research awards.The Albert and Mary Lasker Foundation also announced Wednesday that it was giving its public service award to Planned Parenthood. Each award includes a $250,000 honorarium.The foundation's clinical research award is shared by Dr. Douglas Lowy and John Schiller of the U.S. National Cancer Institute. In the early 1990s they began work that would eventually lead to vaccines against human papillomavirus, or HPV, which causes cervical cancer and some other cancers.
NYS Entity Status
NYS Filing Date
FEBRUARY 01, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2013 - CANCER AND BLOOD MEDICAL SERVICES OF NEW YORK, P.C.
Around the Web
- 3 scientists, Planned Parenthood win Lasker medical prizes
By MALCOLM RITTER, AP Science Writer - Wednesday Sep 6, 2017
- SF hospital starts umbilical cord blood donation effort
By John King - Wednesday Jul 26, 2017
New parents in San Francisco can now donate their infant’s umbilical cord blood for use in transplants or medical research.Usable blood is sent to the Cleveland Cord Blood Center in Ohio, where it is stored and placed in a registry that is available free for public use and can be drawn on by doctors in the United States and 17 other countries.Doctors use it as an alternative for bone marrow transplants in treating cancer patients.The state Legislature voted in 2010 to increase birth certificate fees by $2 as a way to fund a statewide effort, the Umbilical Cord Blood Collection Program, which is managed by UC Davis.
- FDA approves 1st gene therapy treatment for cancer
By Catherine Ho - Wednesday Aug 30, 2017
The Food and Drug Administration on Wednesday approved the first gene therapy treatment for cancer, green-lighting Novartis Pharmaceuticals’ cell therapy treatment for childhood leukemia. The regulatory approval had been widely expected but came earlier than analysts’ predictions. It signals that other drug companies developing cell-therapy treatments may also be able to commercialize what medical experts say is a revolutionary new form of medicine. The therapy extracts a patient’s cells from his or her blood, sends them to a manufacturing site to genetically modify them, and then re-infuses them into the person’s body to attack cancer cells.
- With FDA Nod, Agios, Celgene Get Speedy OK For Blood Cancer Drug
By Ben Fidler - Tuesday Aug 1, 2017
[Updated, 2:10 pm ET, see below] The FDA approved a new blood cancer drug today. Called enasidenib (Idhifa), it’s the latest therapy sold by Celgene, the big cancer drugmaker from Summit, NJ. But the news is significant for other reasons. The drug is the first product to come from the labs of Agios Pharmaceuticals (NASDAQ: […]
- Mets claim medical service company stole their trademark
By Richard Morgan - Tuesday Aug 1, 2017
Just when the Mets thought their season couldn’t get any worse — a Florida company has come along and “stolen” its trademark, the team contends. Comprehensive Health Services, a source for workforce medical services, registered a “METS” trademark for its proprietary Medical Exam Tracking System, trademark records show. The Cape Canaveral-based METS, according to the...
- Expanding Teladoc Adds Network, Tech With $440M Best Doctors Deal
By David Holley - Tuesday Jun 20, 2017
Dallas—In Teladoc’s acquisition of Boston-based Best Doctors—a $440 million cash-and-stock deal that the companies announced Monday—Teladoc (NYSE: TDOC) is gaining a business that lets it offer more specialization in its telemedicine services. Best Doctors connects individuals who have tough decisions to make about treatments—or who want a second opinion about a diagnosis—with top-rated doctors worldwide. […]